Renalytix Management
Management criteria checks 1/4
Renalytix's CEO is James McCullough, appointed in Mar 2018, has a tenure of 6.17 years. total yearly compensation is $1.04M, comprised of 58% salary and 42% bonuses, including company stock and options. directly owns 1.78% of the company’s shares, worth £755.25K. The average tenure of the management team and the board of directors is 6.2 years and 0.8 years respectively.
Key information
James McCullough
Chief executive officer
US$1.0m
Total compensation
| CEO salary percentage | 58.0% |
| CEO tenure | 6.2yrs |
| CEO ownership | 1.8% |
| Management average tenure | 6.2yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$42m |
| Sep 30 2023 | n/a | n/a | -US$44m |
| Jun 30 2023 | US$1m | US$601k | -US$46m |
| Mar 31 2023 | n/a | n/a | -US$40m |
| Dec 31 2022 | n/a | n/a | -US$42m |
| Sep 30 2022 | n/a | n/a | -US$47m |
| Jun 30 2022 | US$636k | US$601k | -US$45m |
| Mar 31 2022 | n/a | n/a | -US$50m |
| Dec 31 2021 | n/a | n/a | -US$44m |
| Sep 30 2021 | n/a | n/a | -US$38m |
| Jun 30 2021 | US$1m | US$586k | -US$35m |
| Mar 31 2021 | n/a | n/a | -US$28m |
| Dec 31 2020 | n/a | n/a | -US$20m |
| Sep 30 2020 | n/a | n/a | -US$16m |
| Jun 30 2020 | US$488k | US$470k | -US$10m |
| Mar 31 2020 | n/a | n/a | US$28m |
| Dec 31 2019 | n/a | n/a | -US$8m |
| Sep 30 2019 | n/a | n/a | -US$5m |
| Jun 30 2019 | US$216k | US$269k | -US$42m |
Compensation vs Market: James's total compensation ($USD1.04M) is above average for companies of similar size in the UK market ($USD349.23K).
Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.
CEO
James McCullough (55 yo)
6.2yrs
Tenure
US$1,036,321
Compensation
Mr. James R. McCullough, M.B.A. is Co-Founder and has been the Chief Executive Officer of Renalytix Plc (formerly, Renalytix AI plc) since March 15, 2018 and served as its Executive Director. Mr. McCulloug...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 6.2yrs | US$1.04m | 1.78% $ 755.3k | |
| Chief Financial Officer | 6.2yrs | US$623.68k | 1.17% $ 496.4k | |
| Chief Technology Officer | 6.2yrs | no data | 0.37% $ 156.6k | |
| President & Chief Business Officer | less than a year | no data | no data | |
| Company Secretary | no data | no data | no data |
6.2yrs
Average Tenure
55yo
Average Age
Experienced Management: RENX's management team is seasoned and experienced (6.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Non-Executive Director | 2.8yrs | US$24.00k | 0% $ 0 | |
| Independent Non-Executive Director | 5.5yrs | US$24.00k | no data | |
| Independent Non-Executive Chairman | 6.2yrs | US$24.00k | 6.52% $ 2.8m | |
| Member of Clinical Advisory Board | less than a year | no data | no data | |
| Member of Clinical Advisory Board | less than a year | no data | no data | |
| Member of Clinical Advisory Board | less than a year | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | 4.8yrs | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | 0% $ 0 | |
| Member of Clinical Advisory Board | less than a year | no data | no data | |
| Member of Clinical Advisory Board | less than a year | no data | no data | |
| Member of Clinical Advisory Board | less than a year | no data | no data |
0.8yrs
Average Tenure
63.5yo
Average Age
Experienced Board: RENX's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.